NCT07104487View on ClinicalTrials.gov

[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2029

Conditions
Stroke (CVA) or TIACarotid Artery PlaqueAtherosclerosis Cardiovascular DiseaseCarotid Arteriosclerosis
Interventions
DRUG

[18F]AlF-OC

Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with 0.9% NaCl.

Trial Locations (1)

3000

RECRUITING

UZ Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER